Panacea Biotec is currently trading at Rs. 117.65, up by 1.80 points or 1.55% from its previous closing of Rs. 115.85 on the BSE.
The scrip opened at Rs. 117.00 and has touched a high and low of Rs. 122.30 and Rs. 114.50 respectively. So far 10341 shares were traded on the counter.
The BSE group ‘B’ stock of face value Rs. 1 has touched a 52 week high of Rs. 219.00 on 27-Feb-2019 and a 52 week low of Rs. 112.95 on 06-Dec-2019.
Last one week high and low of the scrip stood at Rs. 123.10 and Rs. 112.95 respectively. The current market cap of the company is Rs. 722.76 crore.
The promoters holding in the company stood at 73.59%, while Institutions and Non-Institutions held 1.80% and 24.61% respectively.
Panacea Biotec has launched a brand ViLACT in India, available in four formulations (ViLACT, ViLACT M500, ViLACT M850 and ViLACT M1000). ViLACT is used in the treatment of Uncontrolled Type 2 Diabetes Mellitus patients.
Panacea Biotec is a leading research based Biotechnology Company with established research, manufacturing and marketing capabilities.